Medication
Afinitor Disperz
DIN 02425645 · Novartis Pharmaceuticals Canada Inc
What it is
- Active ingredients
- Everolimus — 2 mg
- Form and route
- Tablet For Suspension · Oral
- Schedule
- PRESCRIPTION
- Authorised since
- 2014-11-28
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
No other medication authorised in Canada shares this active ingredient.
Health Canada groups products by their active ingredients. No other marketed product shares this one’s group, which usually means it is still the only authorised version — not that alternatives were hidden or missed.
Ontario Drug Benefit coverage
As of 31 July 2026This medication is not listed on the Ontario Drug Benefit formulary.
Not on the formulary is not the same as not covered. Private and workplace insurance, federal programs such as Non-Insured Health Benefits and Veterans Affairs, and every other province’s public plan are all outside what this page shows — Ontario is the only province RxMonitor holds coverage data for. Ontario may also fund a product that is not on the formulary through the Exceptional Access Program.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Antineoplastic and immunomodulating agents
- ATC code
- L04AH02
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of L04AH02, see the WHO ATC/DDD Index.
Recalls and safety alerts
Recall matching is not available yet.
RxMonitor does not yet match Health Canada recalls to individual products — that arrives in a later release. Nothing on this page should be read as confirming that this medication has not been recalled.